Doctor profile · Federal record

Dr. Padmaja Venuturumilli, MD

Medical Oncology Physician (CMS: Medical Oncology) · Pediatrics Physician · Royal Oak, MI

  • NPI 1548475387
  • Accepts Medicare
  • 35 yrs in practice
  • Female
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
3577 W 13 Mile RD Ste 103
Royal Oak, MI 480736710
(248) 288-4500
Mailing address
26901 Beaumont Blvd Ste 3D
Southfield, MI 480333849

Credentials & registration

NPPES · NUCC
NPI registered
May 2007 — 19 yrs on file
Profile last updated
October 23, 2020
Year of graduation
1991 — 35 yrs since
Specialty taxonomy
207RX0202X — NUCC code
State license (1)
Michigan #4301081584

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1548475387. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
84,788
Distinct HCPCS
10
Medicare allowed
$788,527
HCPCS Description Services Patients Avg allowed
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) 24,990 40 $0
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram 23,400 25 $0
J1453 Injection, fosaprepitant, 1 mg 9,150 23 $0
J9271 Injection, pembrolizumab, 1 mg 6,000 17 $54
J0897 Injection, denosumab, 1 mg 5,760 23 $23
J9041 Injection, bortezomib, 0.1 mg 1,645 12 $5
J2469 Injection, palonosetron hcl, 25 mcg 1,330 51 $1
36415 Insertion of needle into vein for collection of blood sample 1,249 464 $8
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 1,228 447 $7
J0640 Injection, leucovorin calcium, per 50 mg 1,056 16 $4

In context: peer comparison

Among 1 peers in this city , average services per provider: 1,662. This provider delivers 51× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$2,435
Transactions
67
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Novartis Pharmaceuticals Corporation 24 $1,253.55
Eisai Inc. 7 $134.58
Merck Sharp & Dohme LLC 4 $98.20
Gilead Sciences, Inc. 5 $87.56
Genentech USA, Inc. 4 $87.51
Janssen Biotech, Inc. 3 $77.48
PFIZER INC. 4 $74.28
AstraZeneca Pharmaceuticals LP 3 $66.07
Rigel Pharmaceuticals, Inc. 3 $60.04
TAIHO ONCOLOGY, INC. 2 $41.91
Takeda Pharmaceuticals U.S.A., Inc. 2 $35.32
Celgene Corporation 2 $33.55
ABBVIE INC. 2 $31.80
Acrotech Biopharma Inc. 1 $28.65
Immunocore Limited 1 $25.94

By nature of payment

Food and Beverage
$1,304
Long term medical supply or device loan
$1,131

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
592
Patients
131
Total drug cost
$303,548
Drug Type Claims Patients Total cost
Anastrozole Generic 274 75 $12,457
Exemestane Generic 53 15 $13,859
Eliquis (Apixaban) Brand 50 19 $67,320
Dexamethasone Generic 32 0 $584
Hydroxyurea Generic 27 0 $1,367
Prochlorperazine Maleate Generic 26 22 $955
Famotidine Generic 16 0 $97
Omeprazole Generic 16 0 $393
Fentanyl Generic 15 0 $2,034
Folic Acid Generic 15 0 $68

Hospital affiliations

CMS Hospital Compare

Frequently asked questions

Auto-generated from federal data
What is Dr. Padmaja Venuturumilli's medical specialty?
Dr. Padmaja Venuturumilli practices Medical Oncology Physician in Royal Oak, MI.
Where does Dr. Padmaja Venuturumilli practice?
Dr. Padmaja Venuturumilli practices at 3577 W 13 Mile RD Ste 103, Royal Oak, MI 480736710. Office phone: 2482884500.
What is Dr. Padmaja Venuturumilli's NPI?
Dr. Padmaja Venuturumilli's National Provider Identifier (NPI) is 1548475387, issued by NPPES.
Does Dr. Padmaja Venuturumilli accept Medicare assignment?
Yes. Dr. Padmaja Venuturumilli accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Padmaja Venuturumilli commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS Q5110); Injection, fosaprepitant, 1 mg (HCPCS J1453). Source: CMS Medicare Physician & Other Practitioners file.